Highlights

  • Northeast Georgia Health System went live with Salix in July 2026, becoming Artrya’s second revenue-generating US customer.
  • Tanner Health is using Salix Coronary Anatomy and Coronary Plaque routinely across five hospitals, generating subscription and fee-per-scan revenue.
  • Artrya completed validation and pre-submission activities for Salix Coronary Flow, with FDA submission described as imminent.
  • Coronary Flow is targeted for FDA clearance and commercial launch in the second half of calendar 2026 and is eligible for an existing US$877-per-scan reimbursement code once cleared.
  • Artrya reported a pro forma cash position of A$74.0 million at 30 June 2026, supporting continued US commercial and regulatory activity.

Artrya (ASX:AYA) is moving into a different stage of its US expansion. The Perth-based medical technology company is no longer focused only on obtaining regulatory clearances for its cardiac imaging software; it is now trying to turn those approvals into routine clinical use, hospital deployments and recurring revenue.

That transition became more visible in July 2026 when Northeast Georgia Health System (NGHS) went live with the Salix platform and began generating revenue, becoming Artrya’s second paying US customer.

At the same time, the company is progressing Salix Coronary Flow toward a US Food and Drug Administration 510(k) submission, potentially adding another reimbursable module to its existing Anatomy and Plaque products.

The longer-term question is whether Artrya can turn this expanding product suite into repeatable adoption across US hospital systems.

Building an Integrated Cardiac Imaging Platform

Artrya develops artificial intelligence-powered software designed to assist clinicians in assessing coronary artery disease from Coronary Computed Tomography Angiography (CCTA) scans.

Its Salix platform is structured around several modules rather than a single diagnostic tool.

Salix Coronary Anatomy assesses coronary anatomy, while Salix Coronary Plaque identifies and quantifies plaque. Coronary Flow is intended to add physiological blood-flow assessment using Fractional Flow Reserve measurements derived from standard CT scans.

Once all three modules are available commercially, the platform is intended to combine anatomical, plaque and physiological information within a single CCTA examination.

This modular approach is important commercially because hospitals can potentially expand usage over time while Artrya generates revenue from more than one component of the same clinical workflow.

A Second US Customer Moves Into Routine Use

Artrya announced on 23 July 2026 that its Salix platform had gone live at NGHS, with patient scans being processed and revenue commencing.

The initial deployment covers the first of NGHS’ five hospitals and outpatient facilities, with broader rollout planned across the network. Salix Coronary Anatomy is expected to generate monthly subscription revenue, while Coronary Plaque generates fee-per-scan revenue as eligible CCTA scans are analysed.

The importance of the deployment lies less in the addition of one customer and more in demonstrating that Salix can be integrated into routine hospital workflows.

Hospital technology adoption typically requires clinical training, IT integration, reimbursement processes and physician acceptance. Moving from contract signing to active patient scans is therefore a more meaningful commercial milestone than a customer announcement alone.

Tanner Health Provides an Earlier Reference Case

Tanner Health remains Artrya’s most advanced US commercial customer.

During the June 2026 quarter, Salix Coronary Anatomy and Coronary Plaque were fully operational and being used routinely across Tanner Health’s five hospitals. The deployment was supporting higher scan volumes alongside subscription and fee-per-scan revenue.

Artrya has also been working with Tanner Health on reimbursement workflows and pre-authorisation processes.

These activities could become relevant to wider commercial scaling because a medical technology platform needs more than technical integration to achieve routine usage. It also needs a practical process through which hospitals can bill for eligible assessments.

Artrya indicated that these workflow initiatives are intended to support deployment and reimbursement as additional US health systems adopt Salix.

Cone Health Could Broaden the Foundation Customer Base

A third US foundation customer, Cone Health, remained in integration during the June quarter.

Artrya’s customer-success team has been working with cardiology and IT teams to progress the platform toward clinical deployment.

The company’s stated objective is for all three foundation customers to generate Anatomy and Plaque revenue by the end of the September quarter.

If achieved, this would provide Artrya with three operating US hospital-system references rather than relying primarily on Tanner Health.

That matters because future hospital customers may place significant weight on evidence that the technology is already being used successfully in comparable clinical environments.

Coronary Flow Is the Next Regulatory Step

Artrya’s next major product milestone is Salix Coronary Flow.

The company reported that validation and pre-submission activities were completed during the June quarter after required US clinical datasets were secured. Its FDA 510(k) submission was described as imminent, with clearance and commercial launch targeted for the second half of calendar 2026.

Coronary Flow is designed to provide near real-time, non-invasive assessment of blood flow from standard CT scans and generate Fractional Flow Reserve measurements that may help clinicians determine whether invasive angiography is necessary.

Once cleared, assessments are expected to be eligible for an existing Category I CPT reimbursement code currently valued at US$877 per scan.

That creates a potential additional fee-per-scan revenue stream at hospitals already using the Salix platform.

SAPPHIRE Supports Both Evidence and Commercialisation

Artrya also commenced the SAPPHIRE Study, with investigators from participating US health systems meeting in San Diego on 9 July 2026.

The study will evaluate Salix Coronary Plaque and Artrya’s Plaque Dispersion Score in coronary artery disease identification, risk stratification and management.

Its importance extends beyond clinical evidence.

Artrya is also using SAPPHIRE as part of its commercialisation strategy by placing Salix inside participating health systems and creating opportunities to convert research relationships into longer-term commercial customers.

This approach could potentially lower the gap between clinical validation and commercial adoption if participating hospitals become familiar with the platform during the study.

Cash Provides Runway for the US Strategy

Artrya reported a pro forma cash position of A$74.0 million at 30 June 2026.

During the June quarter, customer receipts were A$0.06 million, reflecting the still-early stage of commercialisation. Operating costs excluding interest income and the Research and Development rebate were A$6.4 million, down from A$6.8 million in the preceding quarter.

The contrast between the cash balance and current customer receipts illustrates the nature of the business.

Artrya has substantial financial resources relative to its early revenue base, but it still needs to demonstrate that hospital adoption can eventually produce enough recurring revenue to offset ongoing product-development and commercialisation expenditure.

Reimbursement Could Shape Revenue Economics

Artrya’s commercial model combines subscription revenue with usage-based income.

At NGHS, Coronary Anatomy generates monthly software subscription fees, while Coronary Plaque generates fee-per-scan revenue. Coronary Flow is expected to add another fee-per-scan stream once regulatory clearance is achieved.

That structure creates potential revenue expansion within existing hospital customers.

Rather than relying solely on adding more sites, Artrya may be able to increase revenue per hospital as scan volumes rise and additional modules are activated.

However, reimbursement also introduces execution complexity. Hospitals need efficient workflows for billing and pre-authorisation, and actual utilisation depends on physicians incorporating Salix into routine clinical practice.

Risks Remain Material

Artrya remains an early-stage commercial medical technology company.

The most immediate risk is regulatory timing. Coronary Flow has not yet received FDA clearance, and additional questions or requirements could delay submission review or commercial launch.

Customer concentration is another issue. Two revenue-generating US hospital systems remain a small base from which to extrapolate broader adoption.

Hospital sales cycles can also be lengthy, with contracts requiring integration, training, reimbursement preparation and clinical acceptance before generating material revenue.

Cash remains substantial, but continued development and US expansion will consume capital while revenue is still emerging.

Competition is also relevant as multiple cardiac imaging and artificial intelligence providers pursue opportunities in CCTA assessment.

What Matters From Here

The next phase will be defined by execution rather than regulatory headlines alone.

Investors can monitor whether NGHS expands Salix across its broader five-hospital network, whether Cone Health progresses into revenue-generating clinical use, and whether scan volumes continue increasing at Tanner Health.

The Coronary Flow FDA submission and any subsequent clearance decision will remain important because the module would complete Artrya’s initial integrated Salix suite.

Progress across SAPPHIRE sites could also provide an indication of the company’s future hospital pipeline.

Finally, customer receipts and operating cash expenditure will show whether commercial adoption is beginning to reduce the gap between Artrya’s technology investment and its revenue base.

Conclusion

Artrya’s US strategy is beginning to shift from product approval toward real-world hospital adoption.

NGHS becoming the second revenue-generating customer in July 2026 adds another reference site alongside Tanner Health, while Cone Health remains in integration.

At the same time, Salix Coronary Flow is approaching FDA submission, potentially adding physiological blood-flow assessment and another reimbursable revenue stream to the platform.

With A$74.0 million in pro forma cash at 30 June 2026, Artrya has financial capacity to continue pursuing its US rollout.

The longer-term test is whether multiple hospital deployments, higher scan volumes and a broader Salix module suite can turn early clinical adoption into a repeatable commercial model.